Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Blueprint Medicines Corpo...

    NASDAQ: BPMC · Real-Time Price · USD
    127.97
    -0.24 (-0.19%)
    At close: Jun 13, 2025, 3:59 PM
    127.96
    -0.01%
    After-hours: Jun 13, 2025, 05:27 PM EDT

    Blueprint Medicines Statistics

    Share Statistics

    Blueprint Medicines has 64.58M shares outstanding. The number of shares has increased by 2.06% in one year.

    Shares Outstanding

    n/a
    		 64.58M

    Shares Change (YoY)

    n/a
    		 2.06%

    Shares Change (QoQ)

    n/a
    		 0.6%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 62.21M

    Failed to Deliver (FTD) Shares

    n/a
    		 19,752

    FTD / Avg. Volume

    n/a
    		 0.8%

    Short Selling Information

    The latest short interest is 6.08M, so 9.42% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.08M

    Short % of Shares Out

    n/a
    		 9.42%

    Short % of Float

    n/a
    		 10.6%

    Short Ratio (days to cover)

    n/a
    		 8.68

    Valuation Ratios

    The PE ratio is -81.72 and the forward PE ratio is 139.37. Blueprint Medicines's PEG ratio is 0.94.

    PE Ratio

    n/a
    		 -81.72

    Forward PE

    n/a
    		 139.37

    PS Ratio

    n/a
    		 10.77

    Forward PS

    n/a
    		 5

    PB Ratio

    n/a
    		 18.36

    P/FCF Ratio

    n/a
    		 -27.8

    PEG Ratio

    n/a
    		 0.94
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Blueprint Medicines.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.85, with a Debt / Equity ratio of 1.57.

    Current Ratio

    n/a
    		 2.85

    Quick Ratio

    n/a
    		 2.8

    Debt / Equity

    n/a
    		 1.57

    Debt / EBITDA

    n/a
    		 24.39

    Debt / FCF

    n/a
    		 -2.38

    Interest Coverage

    n/a
    		 -3.08

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $746,076.25

    Profits Per Employee

    n/a
    		 $-98,370.97

    Employee Count

    n/a
    		 682

    Asset Turnover

    n/a
    		 0.43

    Inventory Turnover

    n/a
    		 1.48

    Taxes

    Income Tax

    n/a
    		 1.23M

    Effective Tax Rate

    n/a
    		 -1.86%

    Stock Price Statistics

    The stock price has increased by 21.24% in the last 52 weeks. The beta is 0.83, so Blueprint Medicines's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.83

    52-Week Price Change

    n/a
    		 21.24%

    50-Day Moving Average

    n/a
    		 99.63

    200-Day Moving Average

    n/a
    		 95.15

    Relative Strength Index (RSI)

    n/a
    		 75.68

    Average Volume (20 Days)

    n/a
    		 2,466,560

    Income Statement

    In the last 12 months, Blueprint Medicines had revenue of 508.82M and earned -67.09M in profits. Earnings per share was -1.07.

    Revenue

    n/a
    		 508.82M

    Gross Profit

    n/a
    		 488.66M

    Operating Income

    n/a
    		 -212.04M

    Net Income

    n/a
    		 -67.09M

    EBITDA

    n/a
    		 19.23M

    EBIT

    n/a
    		 2.94M

    Earnings Per Share (EPS)

    n/a
    		 -1.07
    Full Income Statement

    Balance Sheet

    The company has 102.01M in cash and 469.11M in debt, giving a net cash position of -367.09M.

    Cash & Cash Equivalents

    n/a
    		 102.01M

    Total Debt

    n/a
    		 469.11M

    Net Cash

    n/a
    		 -367.09M

    Retained Earnings

    n/a
    		 -2.41B

    Total Assets

    n/a
    		 1.2B

    Working Capital

    n/a
    		 451.49M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -192.59M and capital expenditures -4.63M, giving a free cash flow of -197.22M.

    Operating Cash Flow

    n/a
    		 -192.59M

    Capital Expenditures

    n/a
    		 -4.63M

    Free Cash Flow

    n/a
    		 -197.22M

    FCF Per Share

    n/a
    		 -3.14
    Full Cash Flow Statement

    Margins

    Gross margin is 96.04%, with operating and profit margins of -41.67% and -13.19%.

    Gross Margin

    n/a
    		 96.04%

    Operating Margin

    n/a
    		 -41.67%

    Pretax Margin

    n/a
    		 -12.94%

    Profit Margin

    n/a
    		 -13.19%

    EBITDA Margin

    n/a
    		 3.78%

    EBIT Margin

    n/a
    		 -41.67%

    FCF Margin

    n/a
    		 -38.76%

    Dividends & Yields

    BPMC does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BPMC is $129, which is 0.8% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $129

    Price Target Difference

    n/a
    		 0.8%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 19
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 2.13

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist